Guiding light

12 Jan 2006 By Robert Cyran

J&J’s bid isn’t just lower than Boston Scientific’s $25bn rival offer. It hasn’t even increased it to the level that it originally offered. What’s more, the J&J offer is below Guidant’s share price. Guidant’s recommendation is puzzling.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)